Biomarkers for Neoadjuvant Immune Checkpoint Inhibitors
in Non-small Cell Lung Cancer / 中国肺癌杂志
Chinese Journal of Lung Cancer
;
(12): 130-136, 2022.
Article
in Chinese
| WPRIM
| ID: wpr-928790
ABSTRACT
Surgery is the standard treatment for resectable non-small cell lung cancer (NSCLC). Neoadjuvant and adjuvant therapy have been widely used for preventing recurrence and metastasis. Immune checkpoint inhibitors (ICIs) have brought long-term survival benefits in advanced NSCLC and showed higher downstage rates and pathological remission in the neoadjuvant setting. Predictive biomarkers are of great significance to identify the beneficiaries of neoadjuvant ICIs. At present, the biomarkers are still inconclusive. We summarized the clinical trials of neoadjuvant immune checkpoint inhibitors that have been disclosed so far, and reviewed the progress of the biomarkers associated with those trials.
.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Biomarkers
/
Carcinoma, Non-Small-Cell Lung
/
Neoadjuvant Therapy
/
Immune Checkpoint Inhibitors
/
Lung Neoplasms
Type of study:
Prognostic study
Limits:
Humans
Language:
Chinese
Journal:
Chinese Journal of Lung Cancer
Year:
2022
Type:
Article
Similar
MEDLINE
...
LILACS
LIS